6yyd: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 3: Line 3:
<StructureSection load='6yyd' size='340' side='right'caption='[[6yyd]], [[Resolution|resolution]] 1.39&Aring;' scene=''>
<StructureSection load='6yyd' size='340' side='right'caption='[[6yyd]], [[Resolution|resolution]] 1.39&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[6yyd]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Myca9 Myca9]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6YYD OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6YYD FirstGlance]. <br>
<table><tr><td colspan='2'>[[6yyd]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Mycobacteroides_abscessus_ATCC_19977 Mycobacteroides abscessus ATCC 19977]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6YYD OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6YYD FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=Q0H:4-azanyl-6-[1-[[3,4-bis(fluoranyl)phenyl]methyl]pyrazol-4-yl]pyrimidine-5-carbonitrile'>Q0H</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.387&#8491;</td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">purC, MAB_0689 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=561007 MYCA9])</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=Q0H:4-azanyl-6-[1-[[3,4-bis(fluoranyl)phenyl]methyl]pyrazol-4-yl]pyrimidine-5-carbonitrile'>Q0H</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[https://en.wikipedia.org/wiki/Phosphoribosylaminoimidazolesuccinocarboxamide_synthase Phosphoribosylaminoimidazolesuccinocarboxamide synthase], with EC number [https://www.brenda-enzymes.info/php/result_flat.php4?ecno=6.3.2.6 6.3.2.6] </span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6yyd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6yyd OCA], [https://pdbe.org/6yyd PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6yyd RCSB], [https://www.ebi.ac.uk/pdbsum/6yyd PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6yyd ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6yyd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6yyd OCA], [https://pdbe.org/6yyd PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6yyd RCSB], [https://www.ebi.ac.uk/pdbsum/6yyd PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6yyd ProSAT]</span></td></tr>
</table>
</table>
== Function ==
[https://www.uniprot.org/uniprot/PUR7_MYCA9 PUR7_MYCA9]
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
Line 18: Line 19:
</div>
</div>
<div class="pdbe-citations 6yyd" style="background-color:#fffaf0;"></div>
<div class="pdbe-citations 6yyd" style="background-color:#fffaf0;"></div>
==See Also==
*[[SAICAR synthetase|SAICAR synthetase]]
== References ==
== References ==
<references/>
<references/>
Line 23: Line 27:
</StructureSection>
</StructureSection>
[[Category: Large Structures]]
[[Category: Large Structures]]
[[Category: Myca9]]
[[Category: Mycobacteroides abscessus ATCC 19977]]
[[Category: Phosphoribosylaminoimidazolesuccinocarboxamide synthase]]
[[Category: Abell C]]
[[Category: Abell, C]]
[[Category: Blundell TL]]
[[Category: Blundell, T L]]
[[Category: Charoensutthivarakul S]]
[[Category: Charoensutthivarakul, S]]
[[Category: Coyne AG]]
[[Category: Coyne, A G]]
[[Category: Thomas SE]]
[[Category: Thomas, S E]]
[[Category: Ligase]]
[[Category: Phosphoribosylaminoimidazole-succinocarboxamide synthase]]
[[Category: Purc]]
[[Category: Purine biosynthesis]]
[[Category: Saicar synthetase]]

Latest revision as of 16:38, 24 January 2024

Crystal structure of SAICAR Synthetase (PurC) from Mycobacterium abscessus in complex with inhibitorCrystal structure of SAICAR Synthetase (PurC) from Mycobacterium abscessus in complex with inhibitor

Structural highlights

6yyd is a 1 chain structure with sequence from Mycobacteroides abscessus ATCC 19977. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 1.387Å
Ligands:, ,
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

PUR7_MYCA9

Publication Abstract from PubMed

Mycobacterium abscessus (Mab) has emerged as a challenging threat to individuals with cystic fibrosis. Infections caused by this pathogen are often impossible to treat due to the intrinsic antibiotic resistance leading to lung malfunction and eventually death. Therefore, there is an urgent need to develop new drugs against novel targets in Mab to overcome drug resistance and subsequent treatment failure. In this study, SAICAR synthetase (PurC) from Mab was identified as a promising target for novel antibiotics. An in-house fragment library screen and a high-throughput X-ray crystallographic screen of diverse fragment libraries were explored to provide crucial starting points for fragment elaboration. A series of compounds developed from fragment growing and merging strategies, guided by crystallographic information and careful hit-to-lead optimization, have achieved potent nanomolar binding affinity against the enzyme. Some compounds also show a promising inhibitory effect against Mab and Mtb. This work utilizes a fragment-based design and demonstrates for the first time the potential to develop inhibitors against PurC from Mab.

Development of Inhibitors of SAICAR Synthetase (PurC) from Mycobacterium abscessus Using a Fragment-Based Approach.,Charoensutthivarakul S, Thomas SE, Curran A, Brown KP, Belardinelli JM, Whitehouse AJ, Acebron-Garcia-de-Eulate M, Sangan J, Gramani SG, Jackson M, Mendes V, Floto RA, Blundell TL, Coyne AG, Abell C ACS Infect Dis. 2022 Feb 11;8(2):296-309. doi: 10.1021/acsinfecdis.1c00432. Epub , 2022 Jan 17. PMID:35037462[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Charoensutthivarakul S, Thomas SE, Curran A, Brown KP, Belardinelli JM, Whitehouse AJ, Acebron-Garcia-de-Eulate M, Sangan J, Gramani SG, Jackson M, Mendes V, Floto RA, Blundell TL, Coyne AG, Abell C. Development of Inhibitors of SAICAR Synthetase (PurC) from Mycobacterium abscessus Using a Fragment-Based Approach. ACS Infect Dis. 2022 Feb 11;8(2):296-309. doi: 10.1021/acsinfecdis.1c00432. Epub , 2022 Jan 17. PMID:35037462 doi:http://dx.doi.org/10.1021/acsinfecdis.1c00432

6yyd, resolution 1.39Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA